/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2026-04-20 15:12:132026-04-21 12:49:51Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK-012 in First-Line Non-Squamous NSCLC in Oral Presentation at AACR 2026
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2026-03-17 12:29:212026-03-17 12:48:04Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK 012 in First Line Nonsquamous NSCLC with Features of Immunotherapy Resistance
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2026-02-25 12:17:372026-02-25 13:10:30Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2026-02-20 10:32:432026-02-20 14:42:07Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2025-11-06 14:55:042025-11-07 06:35:51Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2025-10-29 14:00:582025-11-06 14:52:21Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual Meeting
/wp-content/uploads/logo-300x63.png00Jake Robison/wp-content/uploads/logo-300x63.pngJake Robison2024-11-15 05:01:302024-11-15 05:02:52Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024
/wp-content/uploads/logo-300x63.png00Jake Robison/wp-content/uploads/logo-300x63.pngJake Robison2024-11-08 05:05:072024-11-15 04:55:42Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
